⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNY News
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight
prnewswire.com
LIVN
PTC
UCB
XENE
AQST
TAK
BHVN
KNOP
VRTX
SUPN
GSK
SNY
MD
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
globenewswire.com
REGN
SNY
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
globenewswire.com
SNY
REGN
Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million
globenewswire.com
ALV
SNY
LLY
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
globenewswire.com
SNY
More Than 30 Million Americans Living with Rare Diseases
prnewswire.com
AMGN
SNY
AGIO
ASND
DVA
INCY
NVS
PFE
REGN
UCB
Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market Report 2026-2032: Revenues to Grow by $750M at 8.64% CAGR
globenewswire.com
ABBV
AMGN
PFE
BMY
MRK
REGN
SNY
TAK
NVS
GSK
HRTX
Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases
prnewswire.com
SNY
Cedar Health Research and Texas Native Health Expand Partnership with Embedded Clinical Research Site to Increase Patient Access to Trials
prnewswire.com
LLY
AMGN
SNY
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
globenewswire.com
SNY